BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34273058)

  • 1. Current Perspectives on Severe Drug Eruption.
    Zhang J; Lei Z; Xu C; Zhao J; Kang X
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):282-298. PubMed ID: 34273058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
    Mustafa SS; Ostrov D; Yerly D
    Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse cutaneous drug eruptions: current understanding.
    Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
    Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
    Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
    Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug reaction with eosinophilia and systemic symptoms].
    Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
    Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
    Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
    Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
    Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.
    Walsh SA; Creamer D
    Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
    Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
    Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe cutaneous adverse reactions related to systemic antibiotics.
    Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
    Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
    Godfrey H; Jedlowski P; Thiede R
    Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
    Owen CE; Jones JM
    Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
    Loo CH; Tan WC; Khor YH; Chan LC
    Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
    Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
    Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
    AlJasser MI
    Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention.
    Zhang C; Van DN; Hieu C; Craig T
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):483-487. PubMed ID: 31400461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping
    Jantararoungtong T; Tempark T; Koomdee N; Medhasi S; Sukasem C
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1049-1064. PubMed ID: 34148467
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy.
    Mockenhaupt M
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):142-60; quiz 161-2. PubMed ID: 19371237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
    Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
    J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017.
    Kim HK; Kim DY; Bae EK; Kim DW
    J Korean Med Sci; 2020 Feb; 35(4):e17. PubMed ID: 31997613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.